In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus
Weeks after bowing out of a billion-dollar deal with Aduro Biotech, J&J is back to the drawing board with another oncology licensing pact that, if fruitful, could pit them directly against AstraZeneca’s lung cancer star Tagrisso.
Korean drugmaker Yuhan is collecting $50 million upfront on the deal, which centers around lazertinib, a third-generation EGFR tyrosine-kinase inhibitor designed to target multiple mutations of the receptor. With worldwide rights to the asset — except for South Korea — J&J will take over development, manufacturing and commercialization while collaborating with Yuhan on clinical trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.